This paper is in the following e-collection/theme issue:

RCTs - Protocols/Proposals (funded, already peer-reviewed, non-eHealth) (174)

Published on in Vol 9, No 4 (2020): April

Efficacy and Safety of Rituximab in Refractory CIDP With or Without IgG4 Autoantibodies (RECIPE): Protocol for a Double-Blind, Randomized, Placebo-Controlled Clinical Trial

Efficacy and Safety of Rituximab in Refractory CIDP With or Without IgG4 Autoantibodies (RECIPE): Protocol for a Double-Blind, Randomized, Placebo-Controlled Clinical Trial

Efficacy and Safety of Rituximab in Refractory CIDP With or Without IgG4 Autoantibodies (RECIPE): Protocol for a Double-Blind, Randomized, Placebo-Controlled Clinical Trial

Authors of this article:

Shinobu Shimizu1 Author Orcid Image ;   Masahiro Iijima1, 2 Author Orcid Image ;   Yuki Fukami2 Author Orcid Image ;   Natsuko Tamura1, 3 Author Orcid Image ;   Masahiro Nakatochi1, 4 Author Orcid Image ;   Masahiko Ando1 Author Orcid Image ;   Ryoji Nishi2 Author Orcid Image ;   Haruki Koike2 Author Orcid Image ;   Kenichi Kaida5 Author Orcid Image ;   Michiaki Koga6 Author Orcid Image ;   Takashi Kanda6 Author Orcid Image ;   Hidenori Ogata7 Author Orcid Image ;   Jun-Ichi Kira7 Author Orcid Image ;   Masahiro Mori8 Author Orcid Image ;   Satoshi Kuwabara8 Author Orcid Image ;   Masahisa Katsuno2 Author Orcid Image
Article Authors Cited by (29) Tweetations (2) Metrics
All Time | Last Month | Last Six Months | Last Year
JMIR Publications JMIR Publications @jmirpub

JMIR Res Protocols: Efficacy and Safety of Rituximab in Refractory CIDP With or Without IgG4 Autoantibodies (RECIPE… https://t.co/a5s3Q38bCv

2:08 PM · Apr 01, 2020

0
0
bokemontaro bokemontaro @hichachu

Efficacy and Safety of Rituximab in Refractory CIDP With or Without IgG4 Autoantibodies (RECIPE): Protocol for a Do… https://t.co/vzkYN2auKY

10:26 AM · Jun 01, 2022

0
0